Tumor Suppressor Protein p53
"Tumor Suppressor Protein p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
| Descriptor ID |
D016159
|
| MeSH Number(s) |
D12.776.157.687.650 D12.776.260.820 D12.776.624.776.775 D12.776.660.720.650 D12.776.744.845
|
| Concept/Terms |
Tumor Suppressor Protein p53- Tumor Suppressor Protein p53
- p53 Antigen
- TP53 Protein
- TRP53 Protein
- p53 Tumor Suppressor Protein
- pp53 Phosphoprotein
- Phosphoprotein, pp53
- Cellular Tumor Antigen p53
- Oncoprotein p53
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Protein p53".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Protein p53".
This graph shows the total number of publications written about "Tumor Suppressor Protein p53" by people in this website by year, and whether "Tumor Suppressor Protein p53" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 3 | 5 |
| 1996 | 3 | 4 | 7 |
| 1997 | 2 | 3 | 5 |
| 1998 | 3 | 4 | 7 |
| 1999 | 1 | 1 | 2 |
| 2000 | 3 | 4 | 7 |
| 2001 | 4 | 2 | 6 |
| 2002 | 9 | 9 | 18 |
| 2003 | 7 | 3 | 10 |
| 2004 | 9 | 2 | 11 |
| 2005 | 6 | 4 | 10 |
| 2006 | 8 | 5 | 13 |
| 2007 | 3 | 7 | 10 |
| 2008 | 5 | 11 | 16 |
| 2009 | 3 | 2 | 5 |
| 2010 | 11 | 5 | 16 |
| 2011 | 8 | 9 | 17 |
| 2012 | 5 | 7 | 12 |
| 2013 | 5 | 1 | 6 |
| 2014 | 8 | 5 | 13 |
| 2015 | 7 | 6 | 13 |
| 2016 | 6 | 5 | 11 |
| 2017 | 8 | 4 | 12 |
| 2018 | 5 | 7 | 12 |
| 2019 | 7 | 7 | 14 |
| 2020 | 5 | 4 | 9 |
| 2021 | 5 | 3 | 8 |
| 2022 | 5 | 6 | 11 |
| 2023 | 2 | 9 | 11 |
| 2024 | 8 | 5 | 13 |
| 2025 | 5 | 2 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Protein p53" by people in Profiles.
-
Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2025 May 15; 31(10):1831-1840.
-
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer J. 2025 May 07; 15(1):88.
-
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment. J Clin Invest. 2025 May 15; 135(10).
-
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases. Am J Hematol. 2025 Jun; 100(6):1010-1018.
-
TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025 Jun; 100 Suppl 4:88-115.
-
Microbiota does not influence tumor development in two models of heritable cancer. mBio. 2025 Mar 12; 16(3):e0386624.
-
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Am J Hematol. 2025 Apr; 100(4):552-560.
-
Cancer cells restrict immunogenicity of retrotransposon expression via distinct mechanisms. Immunity. 2024 12 10; 57(12):2879-2894.e11.
-
What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 2024 Nov 19; 14(1):202.
-
Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms. Br J Haematol. 2025 Apr; 206(4):1103-1108.